Table 4.

Outcome risk for ILD subgroups

ILD Subtype	Unadjusted			Adjusted
	HR	95% CI	p-value	HR	95% CI	p-value
Model 1 *
IPAF without MSA/MAA	Ref	Ref	Ref	Ref	Ref	Ref
IPAF-MSA	0.13	0.03–0.55	0.005	0.20	0.05–0.84	0.03
IPAF-MAA	0.65	0.37–1.12	0.12	0.68	0.38–1.21	0.19
IIM-ILD	0.09	0.03–0.30	<0.001	0.17	0.05–0.54	0.003
non-IIM CTD-ILD	0.37	0.25–0.55	<0.001	0.52	0.34–0.80	0.003
IPF	1.11	0.84–1.46	0.47	0.70	0.51–0.97	0.03
Model 2 ∫
IPAF-UIP	Ref	Ref	Ref	Ref	Ref	Ref
IPAF w/o UIP	0.37	0.23–0.61	<0.001	0.46	0.28–0.78	0.004
IPAF-MSA	0.10	0.02–0.41	0.001	0.14	0.03–0.58	0.007
IIM-ILD	0.07	0.02–0.23	<0.001	0.13	0.04–0.42	0.001
non-IIM CTD-ILD	0.28	0.19–0.42	<0.001	0.43	0.27–0.66	<0.001
IPF	0.83	0.62–1.11	0.22	0.63	0.46–0.86	0.003

^*Model 1 adjusted for center, race/ethnicity, presence of UIP, immunosuppressant exposure and GAP stage

^∫Model 2 adjusted for center, race/ethnicity, immunosuppressant exposure and GAP stage

Abbreviations: ILD = interstitial lung disease; IPAF = interstitial pneumonia with autoimmune features; MSA = myositis specific antibody; IIM-ILD = idiopathic inflammatory myopathy-associated ILD; IPF = idiopathic pulmonary fibrosis